

Zealand presents at international healthcare investor conferences in June 2016

Copenhagen, 1 June 2016 – Zealand informs that its senior management will present the company and host investor meetings at the following healthcare investor conferences in June 2016, taking place in New York and London, respectively:

Jefferies 2016 Healthcare Conference, New York – Thursday, 9 June 2016

On Thursday, 9 June 2016, Zealand will hold a group presentation at 3:00 pm EST and host one-on-one investor meetings. Britt Meelby Jensen, President and CEO and Hanne Leth Hillman, Senior Vice President, Investor Relations and Communications will represent the company.

Citi EU Healthcare Conference, London – Tuesday, 21 June 2016

On Tuesday, 21 June 2016, Zealand will host one-to-one investor meetings. Adam Steensberg, Senior Vice President and Chief Medical and Development Officer and Hanne Leth Hillman, Senior Vice President, Investor Relations and Communications will represent the company.

Please note that no new financial or other material information relating to Zealand and its business will be disclosed at these meetings.



For further information, please contact:

Hanne Leth Hillman, Senior Vice President, Investor Relations and Communications
Tel: +45 50 60 36 89, email: hlh@zealandpharma.com

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) ("Zealand") is a biotechnology company with leading scientific expertise in turning peptides into medicines. Zealand has a growing proprietary pipeline of novel investigational medicines and a portfolio of products and projects under license collaborations with Sanofi, Helsinn and Boehringer Ingelheim.

The company's first invented medicine, lixisenatide, a once-daily prandial GLP-1 analogue for the treatment of Type 2 diabetes, is licensed to Sanofi who markets the product globally (ex-US) as Lyxumia[®] and has it under regulatory review in the US. The license agreement with Sanofi covers also iGlarLixi, a fixed-ratio combination of lixisenatide with basal insulin glargine (Lantus[®]) undergoing regulatory review in both the US and Europe.

Zealand's proprietary pipeline of product candidates includes: *ZP4207 (single-dose rescue treatment)* for acute, severe hypoglycemia (Phase II); *ZP1848* for Short Bowel Syndrome (Phase II); *ZP4207 (multiple-dose version)* for better hypoglycemia management in diabetes (Phase I); *ZP2929* for diabetes/obesity (Phase I); and several preclinical peptide therapeutics.

The company is based in Copenhagen (Glostrup), Denmark. For further information about Zealand's business and activities, please visit: www.zealandpharma.com or follow us on Twitter @ZealandPharma